Tela Bio Announces OviTex Inguinal Reinforced Tissue Matri’s European Debut

According to TELA Bio, Inc. (NASDAQ:TELA), OviTex® Inguinal, the only reinforced tissue matrix created especially for laparoscopic and robotically assisted inguinal hernia repair, has entered the European market.

Tela Bio announces OviTex Inguinal Reinforced Tissue Matri's European debut

A specialist surgeon in the operating theatre performing a hernia repair.

This comes after its 2024 U.S. debut, during which it brought in over $1 million in sales. OviTex Inguinal is being introduced in response to the increasing need for natural alternatives to synthetic mesh in hernia treatments. It comes in two anatomically shaped forms that are compatible with trocars. The product will be on display this week in Paris at the European Hernia Society Congress.

OviTex Inguinal expands the line of reinforced tissue matrices produced by TELA Bio, Inc. (NASDAQ:TELA) using minimum polymer and layered ovine rumen. OviTex is backed by more than 40 published or presented studies and has been used in more than 69,000 surgeries worldwide.

A 1.2% recurrence rate over a 1.5-year period was found in a retrospective study headed by Dr. Paul Szotek and included 259 robotic TAPP repairs. The solution supports the growing use of robotic operations and collaborative decision-making between surgeons and patients in Europe.

While we acknowledge the potential of TELA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TELA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.